Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2015 Nov 8

PMID 26545382

Authors

Imelda Marton

Laszlo Krenacs

Eniko Bagdi

Annamaria Bakos

Judit Demeter

Zita Borbenyi

Affiliations

Soon will be listed here.

Abstract

Systemic mastocytosis (SM) is a rare chronic myeloproliferative neoplasm with only limited epidemiologic data published so far. We aimed to analyze the clinical and molecular diagnostic features, and the prognosis and cumulative incidence of SM cases in a cohort of south-eastern Hungarian patients of 13 year follow up. In the period 2001-2013, 35 consecutive SM cases were diagnosed in our regional centre. Immunophenotype, KIT D816V mutation frequency and clinical characteristics, and the prognosis impact of clinical subtypes were tested and compared with published data. Indolent SM (ISM) was diagnosed in 14 patients, SM with an associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) in 15 patients and aggressive SM (ASM) in 6 patients. The KIT D816V mutation was found in 11/14 (78%) of the ISM cases, in 12/15 (80%) of the SM-AHNMD cases and in 5/6 (83%) of the ASM cases. The life expectancy of ISM patients was better, whereas the SM-AHNMD and ASM groups exhibited a reduced median survival. The cumulative incidence for 13 year of the SM was 0.27/10,000. We detected lower 13 year cumulative SM incidence than of published epidemiologic data due to in our analyses involved only those patients who had bone marrow biopsy and histopathologically confirmed SM. This clinical overview clearly showed that the clinical characteristics differ between ISM (UP, anaphylaxis and osteoporosis) and SM-AHNMD/ASM (cytopenia, eosinophilia and splenomegaly).

References

Escribano L, Akin C, Castells M, Orfao A, Metcalfe D . Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002; 81(12):677-90. DOI: 10.1007/s00277-002-0575-z. View

Valent P, Sperr W, Akin C . How I treat patients with advanced systemic mastocytosis. Blood. 2010; 116(26):5812-7. DOI: 10.1182/blood-2010-08-292144. View

Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C . In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood. 2012; 120(24):4846-9. DOI: 10.1182/blood-2011-12-397588. View

Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J . Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009; 124(3):514-21. DOI: 10.1016/j.jaci.2009.05.003. View

Valent P, Akin C, Arock M, Brockow K, Butterfield J, Carter M . Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2011; 157(3):215-25. PMC: 3224511. DOI: 10.1159/000328760. View

Garcia-Montero A, Jara-Acevedo M, Teodosio C, Sanchez M, Nunez R, Prados A . KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108(7):2366-72. DOI: 10.1182/blood-2006-04-015545. View

Schumacher J, Elenitoba-Johnson K, Lim M . Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol. 2007; 61(1):109-14. DOI: 10.1136/jcp.2007.047928. View

BRUNNING R, McKenna R, Rosai J, Parkin J, Risdall R . Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol. 1983; 7(5):425-38. DOI: 10.1097/00000478-198307000-00005. View

Cohen S, Skovbo S, Vestergaard H, Kristensen T, Moller M, Bindslev-Jensen C . Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014; 166(4):521-8. DOI: 10.1111/bjh.12916. View

10.

Tay C, Ong C, Lee V, Pang B . KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting. Pathology. 2013; 45(2):127-37. DOI: 10.1097/PAT.0b013e32835c7645. View

11.

Akin C, Fumo G, Yavuz A, Lipsky P, Neckers L, Metcalfe D . A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004; 103(8):3222-5. DOI: 10.1182/blood-2003-11-3816. View

12.

Pardanani A . How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood. 2013; 121(16):3085-94. DOI: 10.1182/blood-2013-01-453183. View

13.

Ustun C, DeRemer D, Akin C . Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res. 2011; 35(9):1143-52. DOI: 10.1016/j.leukres.2011.05.006. View

14.

Beghini A, Peterlongo P, Ripamonti C, Larizza L, Cairoli R, Morra E . C-kit mutations in core binding factor leukemias. Blood. 2000; 95(2):726-7. View

15.

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L . European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012; 124(23-24):807-14. DOI: 10.1007/s00508-012-0293-z. View

16.

Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O . International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013; 121(13):2393-401. PMC: 3612852. DOI: 10.1182/blood-2012-09-458521. View

17.

Akin C . Clonality and molecular pathogenesis of mastocytosis. Acta Haematol. 2005; 114(1):61-9. DOI: 10.1159/000085563. View

18.

Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K . Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007; 37(6):435-53. DOI: 10.1111/j.1365-2362.2007.01807.x. View

19.

Valent P, Akin C, Sperr W, Horny H, Arock M, Lechner K . Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003; 122(5):695-717. DOI: 10.1046/j.1365-2141.2003.04575.x. View

20.

van Doormaal J, Arends S, Brunekreeft K, van der Wal V, Sietsma J, van Voorst Vader P . Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol. 2012; 131(5):1429-31.e1. DOI: 10.1016/j.jaci.2012.10.015. View